Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.
about
M1-muscarinic receptors promote fear memory consolidation via phospholipase C and the M-currentChemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAMThe antipsychotic potential of muscarinic allosteric modulationAllosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseMuscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaDiscovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research.Development of allosteric modulators of GPCRs for treatment of CNS disordersCrystal structures of the M1 and M4 muscarinic acetylcholine receptorsContribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice.Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers.Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.Selective targeting of G-protein-coupled receptor subtypes with venom peptides.Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease.Novel M(1) allosteric ligands: a patent review.Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophreniaPharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.Molecular conversion of muscarinic acetylcholine receptor M(5) to muscarinic toxin 7 (MT7)-binding protein.Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.Evaluation of an innovative population pharmacokinetic-based design for behavioral pharmacodynamic endpoints.Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes.Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study.The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque.Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes.Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.The snake venom peptide Bj-PRO-7a is a M1 muscarinic acetylcholine receptor agonist.M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease
P2860
Q24612782-5F826A0E-8738-4CD2-AF73-48ACF77D399DQ24631627-B1EBE7EA-8B6C-4325-A60F-BBC3C1B7DE52Q28603221-17292C72-1F50-4BED-A3F6-423FBBCC9851Q28660933-50D0DABF-D0AE-47EC-AA1D-5B5A587858E2Q30459624-5533A125-70B7-4001-AF04-02FD8AE4148AQ30474039-0D62D4D1-8D6A-427C-A0F2-971915B66EB2Q33567120-AA8C3D06-E494-4CE8-A883-5024A28D5FC5Q34373958-D075436C-F8A3-4ABF-9BB1-704AE68D0599Q34517431-5BD78EEA-B03A-4A0E-A631-6505FD37EB08Q35857172-BB618302-DBEF-4D47-82C2-1E1F887D2A8CQ35860873-D264EABA-6D2E-4476-9779-F1465170C619Q37625841-783F4D82-5738-460F-A840-80DF2F2635D7Q37863750-033D95B1-73C9-4FD8-82CD-276F3E7A976CQ37961834-F4834798-D624-4E88-BD75-439DFB5E31D7Q38054855-88AE789C-FA47-4685-888A-3897730CBD0BQ38186705-A62BD9D9-3712-4A8A-A4CA-66FA4156B744Q38286222-2278CF27-8DCB-4416-9C65-7AECFC96A996Q38665289-1AB40574-3146-4FBA-9417-04D66CDA0BA0Q39155961-3BEA4443-EB63-40A4-A9C7-3E6822E094F2Q39765332-57C06EF0-DD16-49A8-A104-6E3E05E58F2AQ41709411-BEE629A0-B35A-4F45-AAA0-7F5FE7E7FC10Q41773074-26CE9D71-F09F-4F6A-8A87-033065953CE1Q41855867-21D31FC2-8C2D-4059-8C2F-C53F1BF46384Q42323359-5EA615C2-ED55-4C5A-A38A-D20BCE590D34Q43713315-DD3DE66D-ECD4-4907-A334-56A57BA35FF8Q48226341-FB4D7B34-CEAD-4EE2-B294-EB778870FF8FQ48430784-48418B69-F4E1-433D-BCDF-6292270F45DDQ48600420-AE363AE8-D992-4D1B-88D9-8DD349973D93Q50694188-BEDFC763-FCB3-4161-9CA0-9007C08600EFQ51771947-146D7146-8F79-4D0E-8097-07A8343DD97BQ58856223-B2D0D11A-7E0A-4065-8FB1-19870A409312
P2860
Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacological comparison of ...... -preferring receptor agonists.
@ast
Pharmacological comparison of ...... -preferring receptor agonists.
@en
Pharmacological comparison of ...... -preferring receptor agonists.
@nl
type
label
Pharmacological comparison of ...... -preferring receptor agonists.
@ast
Pharmacological comparison of ...... -preferring receptor agonists.
@en
Pharmacological comparison of ...... -preferring receptor agonists.
@nl
prefLabel
Pharmacological comparison of ...... -preferring receptor agonists.
@ast
Pharmacological comparison of ...... -preferring receptor agonists.
@en
Pharmacological comparison of ...... -preferring receptor agonists.
@nl
P2093
P1476
Pharmacological comparison of ...... -preferring receptor agonists.
@en
P2093
Albert J Uveges
Angela Kramer
Dianne Kowal
Eugene Tseng
John A Butera
Julia N Heinrich
Karen L Marquis
Mark H Pausch
Mike Popiolek
Scott C Mayer
P356
10.1016/J.EJPHAR.2008.12.044
P407
P577
2009-01-11T00:00:00Z